0001562180-22-003409.txt : 20220414
0001562180-22-003409.hdr.sgml : 20220414
20220414204547
ACCESSION NUMBER: 0001562180-22-003409
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220412
FILED AS OF DATE: 20220414
DATE AS OF CHANGE: 20220414
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Horstmeier Paul
CENTRAL INDEX KEY: 0001780978
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38993
FILM NUMBER: 22828779
MAIL ADDRESS:
STREET 1: C/O HEALTH CATALYST, INC.
STREET 2: 3165 E. MILLROCK DRIVE #400
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Health Catalyst, Inc.
CENTRAL INDEX KEY: 0001636422
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370]
IRS NUMBER: 453337483
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10897 SOUTH RIVER FRONT PARKWAY, #300
CITY: SOUTH JORDAN
STATE: UT
ZIP: 84095
BUSINESS PHONE: 801-708-6800
MAIL ADDRESS:
STREET 1: 10897 SOUTH RIVER FRONT PARKWAY, #300
CITY: SOUTH JORDAN
STATE: UT
ZIP: 84095
FORMER COMPANY:
FORMER CONFORMED NAME: HQC Holdings, Inc.
DATE OF NAME CHANGE: 20150312
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-04-12
false
0001636422
Health Catalyst, Inc.
HCAT
0001780978
Horstmeier Paul
C/O HEALTH CATALYST, INC.
10897 SOUTH RIVER FRONT PARKWAY, #300
SOUTH JORDAN
UT
84095
false
true
false
false
Chief Operating Officer
Common Stock
2022-04-12
4
M
false
520.00
15.84
A
180836.00
D
Common Stock
2022-04-12
4
M
false
4167.00
15.84
A
185003.00
D
Common Stock
2022-04-12
4
M
false
521.00
10.80
A
185524.00
D
Common Stock
2022-04-12
4
S
false
5208.00
25.1623
D
180316.00
D
Stock Option (Right to Buy)
15.84
2022-04-12
4
M
false
4167.00
0.00
D
2029-02-05
Common Stock
4167.00
35402.00
D
Stock Option (Right to Buy)
15.84
2022-04-12
4
M
false
520.00
0.00
D
2029-02-05
Common Stock
520.00
5728.00
D
Stock Option (Right to Buy)
10.80
2022-04-12
4
M
false
521.00
0.00
D
2028-09-27
Common Stock
521.00
18474.00
D
The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person in accordance with Rule 10b5-1.
25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.
25% of the 25,000 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.
25% of the 18,995 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022.
/s/ Jason Alger, as Attorney-in-Fact
2022-04-14